37.08
price down icon0.35%   -0.13
after-market Handel nachbörslich: 36.89 -0.19 -0.51%
loading
Schlusskurs vom Vortag:
$37.21
Offen:
$37.06
24-Stunden-Volumen:
2.46M
Relative Volume:
0.57
Marktkapitalisierung:
$4.19B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-99.15M
KGV:
-39.87
EPS:
-0.93
Netto-Cashflow:
$-74.25M
1W Leistung:
-3.81%
1M Leistung:
-9.07%
6M Leistung:
+29.74%
1J Leistung:
-22.54%
1-Tages-Spanne:
Value
$36.51
$38.50
1-Wochen-Bereich:
Value
$36.25
$39.08
52-Wochen-Spanne:
Value
$18.92
$48.55

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name
Firmenname
Viking Therapeutics Inc
Name
Telefon
858-704-4660
Name
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Name
Mitarbeiter
51
Name
Twitter
@viking_vktx
Name
Nächster Verdiensttermin
2025-10-22
Name
Neueste SEC-Einreichungen
Name
VKTX's Discussions on Twitter

Vergleichen Sie VKTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VKTX
Viking Therapeutics Inc
37.08 4.21B 0 -99.15M -74.25M -0.93
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.04 113.14B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
741.29 78.49B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
877.94 54.76B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
397.55 54.51B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
197.01 41.64B 447.02M -1.18B -906.14M -6.1812

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-29 Eingeleitet Canaccord Genuity Buy
2025-04-29 Eingeleitet Cantor Fitzgerald Overweight
2025-04-08 Eingeleitet Goldman Neutral
2025-02-13 Eingeleitet Scotiabank Sector Outperform
2025-02-07 Eingeleitet Citigroup Neutral
2024-12-02 Eingeleitet Piper Sandler Overweight
2024-11-22 Eingeleitet B. Riley Securities Buy
2024-11-04 Bestätigt H.C. Wainwright Buy
2024-09-11 Eingeleitet JP Morgan Overweight
2024-06-27 Eingeleitet Morgan Stanley Overweight
2024-05-16 Hochstufung Raymond James Outperform → Strong Buy
2024-03-26 Bestätigt Oppenheimer Outperform
2024-03-07 Eingeleitet Jefferies Buy
2024-02-28 Bestätigt Oppenheimer Outperform
2023-05-31 Fortgesetzt ROTH MKM Buy
2023-03-28 Bestätigt Maxim Group Buy
2023-03-17 Eingeleitet Stifel Buy
2021-07-29 Fortgesetzt BTIG Research Buy
2021-05-25 Herabstufung Raymond James Strong Buy → Outperform
2020-06-05 Eingeleitet BMO Capital Markets Outperform
2020-05-05 Eingeleitet Chardan Capital Markets Buy
2020-05-01 Eingeleitet BTIG Research Buy
2019-07-16 Eingeleitet Oppenheimer Outperform
2019-06-25 Eingeleitet Stifel Buy
2019-03-29 Hochstufung SVB Leerink Mkt Perform → Outperform
2019-03-14 Bestätigt Maxim Group Buy
2019-02-22 Eingeleitet SVB Leerink Mkt Perform
2018-12-12 Eingeleitet B. Riley FBR Buy
2018-11-19 Hochstufung Raymond James Outperform → Strong Buy
2018-09-18 Bestätigt H.C. Wainwright Buy
2018-09-18 Bestätigt Maxim Group Buy
2018-09-18 Bestätigt Raymond James Outperform
2018-07-20 Eingeleitet SunTrust Buy
2018-06-28 Eingeleitet Raymond James Outperform
2018-06-01 Bestätigt Laidlaw Buy
2018-05-31 Bestätigt Maxim Group Buy
2018-03-26 Fortgesetzt H.C. Wainwright Buy
2017-11-28 Bestätigt Maxim Group Buy
2017-11-21 Eingeleitet ROTH Capital Buy
Alle ansehen

Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten

pulisher
Dec 13, 2025

2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool

Dec 13, 2025
pulisher
Dec 13, 2025

BlackBarn Capital Partners LP Purchases New Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat

Dec 13, 2025
pulisher
Dec 13, 2025

683 Capital Management LLC Trims Stock Position in Viking Therapeutics, Inc. $VKTX - MarketBeat

Dec 13, 2025
pulisher
Dec 12, 2025

Behavioral Patterns of VKTX and Institutional Flows - news.stocktradersdaily.com

Dec 12, 2025
pulisher
Dec 12, 2025

Is Early VANQUISH-1 Completion And VK2735 Progress Altering The Investment Case For Viking Therapeutics (VKTX)? - simplywall.st

Dec 12, 2025
pulisher
Dec 12, 2025

Frontier Capital Management Co. LLC Increases Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat

Dec 12, 2025
pulisher
Dec 11, 2025

This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street - Yahoo Finance

Dec 11, 2025
pulisher
Dec 11, 2025

3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 - Finviz

Dec 11, 2025
pulisher
Dec 10, 2025

Unusual Bullish Options Activity Could Be A Game Changer For Viking Therapeutics (VKTX) - Yahoo Finance

Dec 10, 2025
pulisher
Dec 10, 2025

Diadema Partners LP Increases Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat

Dec 10, 2025
pulisher
Dec 10, 2025

Viking Therapeutics Faces Pressure as Rival Obesity Drug Data Emerges - Ad-hoc-news.de

Dec 10, 2025
pulisher
Dec 08, 2025

Major Investors Pile Into Viking Therapeutics Stock - Ad-hoc-news.de

Dec 08, 2025
pulisher
Dec 08, 2025

Looking At Viking Therapeutics's Recent Unusual Options Activity - Benzinga

Dec 08, 2025
pulisher
Dec 08, 2025

460,415 Shares in Viking Therapeutics, Inc. $VKTX Acquired by Jump Financial LLC - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

Franklin Resources Inc. Has $703,000 Stock Holdings in Viking Therapeutics, Inc. $VKTX - MarketBeat

Dec 08, 2025
pulisher
Dec 07, 2025

Viking Therapeutics (VKTX): Valuation Check After Faster-Than-Expected Enrollment in Key Obesity Drug Trial - simplywall.st

Dec 07, 2025
pulisher
Dec 07, 2025

Norges Bank Takes $46.85 Million Position in Viking Therapeutics, Inc. $VKTX - MarketBeat

Dec 07, 2025
pulisher
Dec 07, 2025

VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price? - ts2.tech

Dec 07, 2025
pulisher
Dec 06, 2025

Viking Therapeutics: Analysts Project Stock Could More Than Double - AD HOC NEWS

Dec 06, 2025
pulisher
Dec 06, 2025

Viking Therapeutics Stock: Prepping For A Critical 2026 (NASDAQ:VKTX) - Seeking Alpha

Dec 06, 2025
pulisher
Dec 05, 2025

Viking Therapeutics (NASDAQ:VKTX) Shares Up 9.4%Here's Why - MarketBeat

Dec 05, 2025
pulisher
Dec 05, 2025

Schroder Investment Management Group Buys 150,470 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat

Dec 05, 2025
pulisher
Dec 05, 2025

Will Viking Therapeutics Inc. stock outperform Nasdaq index2025 AllTime Highs & Verified Chart Pattern Trade Signals - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

Will Viking Therapeutics Inc. stock outperform international peersEarnings Overview Summary & Low Volatility Stock Suggestions - Newser

Dec 05, 2025
pulisher
Dec 04, 2025

What's Up With The Jump In Viking Therapeutics Stock?Viking Therapeutics (NASDAQ:VKTX) - Benzinga

Dec 04, 2025
pulisher
Dec 04, 2025

The FDA Is Shaking Things Up; Biotech, Research Stocks Diverge - Investor's Business Daily

Dec 04, 2025
pulisher
Dec 04, 2025

How Viking Therapeutics Inc. (1VT) stock expands through international marketsTrade Ideas & Weekly Breakout Opportunity Watchlist - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

What consensus target says about Viking Therapeutics Inc. (1VT) stockMarket Performance Summary & Daily Entry Point Alerts - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Will Viking Therapeutics Inc. stock benefit from sector rotationJuly 2025 Big Picture & Low Drawdown Trading Techniques - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

How Viking Therapeutics Inc. stock responds to policy changesBuy Signal & Growth Oriented Trade Recommendations - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Viking Therapeutics Stock Gains Momentum on Clinical Progress - AD HOC NEWS

Dec 04, 2025
pulisher
Dec 03, 2025

42,134 Shares in Viking Therapeutics, Inc. $VKTX Purchased by Scotia Capital Inc. - MarketBeat

Dec 03, 2025
pulisher
Dec 03, 2025

Why Viking Therapeutics Inc. stock appeals to analysts2025 Pullback Review & Stock Portfolio Risk Management - Newser

Dec 03, 2025
pulisher
Dec 03, 2025

Will Viking Therapeutics Inc. (1VT) stock deliver compounding returnsJuly 2025 Setups & Expert Curated Trade Setups - Newser

Dec 03, 2025
pulisher
Dec 03, 2025

What margin trends mean for Viking Therapeutics Inc. stockEntry Point & Fast Moving Market Watchlists - Newser

Dec 03, 2025
pulisher
Dec 02, 2025

Is There a Future for Viking Therapeutics? - AOL.com

Dec 02, 2025
pulisher
Dec 02, 2025

The Bull Case For Viking Therapeutics (VKTX) Could Change Following Early Completion and Positive Data in Obesity Trial - simplywall.st

Dec 02, 2025
pulisher
Dec 02, 2025

Viking Therapeutics Emerges as a Prime Acquisition Candidate Amid Obesity Drug Advancements - AD HOC NEWS

Dec 02, 2025
pulisher
Dec 02, 2025

XTX Topco Ltd Acquires Shares of 36,199 Viking Therapeutics, Inc. $VKTX - MarketBeat

Dec 02, 2025
pulisher
Dec 02, 2025

Viking Therapeutics, Inc. (VKTX) Options Chain - Yahoo! Finance Canada

Dec 02, 2025
pulisher
Dec 02, 2025

Why Viking Therapeutics Inc. (1VT) stock attracts HNW investorsQuarterly Trade Report & Proven Capital Preservation Methods - Newser

Dec 02, 2025
pulisher
Dec 01, 2025

VKTX Stock Rises 34% in Three Months: Here's What You Should Know - sharewise.com

Dec 01, 2025
pulisher
Dec 01, 2025

Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating - MSN

Dec 01, 2025
pulisher
Dec 01, 2025

Viking Therapeutics Emerges as a Prime Acquisition Target Following Trial Success - AD HOC NEWS

Dec 01, 2025
pulisher
Dec 01, 2025

(VKTX) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com

Dec 01, 2025
pulisher
Dec 01, 2025

Viking Therapeutics Stock Gains Momentum on Clinical Trial Milestone - Ad-hoc-news.de

Dec 01, 2025
pulisher
Dec 01, 2025

Assessing Viking Therapeutics (VKTX) Valuation After Recent Share Price Recovery - Yahoo Finance

Dec 01, 2025
pulisher
Dec 01, 2025

Ensign Peak Advisors Inc Trims Stake in Viking Therapeutics, Inc. $VKTX - MarketBeat

Dec 01, 2025
pulisher
Nov 30, 2025

Viking Therapeutics (VKTX): Evaluating Valuation After Key Phase 3 Obesity Trial Milestone and New Clinical Data - Sahm

Nov 30, 2025
pulisher
Nov 30, 2025

Viking Therapeutics: A Clash of Convictions - Ad-hoc-news.de

Nov 30, 2025
pulisher
Nov 30, 2025

SG Americas Securities LLC Makes New $379,000 Investment in Viking Therapeutics, Inc. $VKTX - MarketBeat

Nov 30, 2025

Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Viking Therapeutics Inc-Aktie (VKTX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Rowland Charles A Jr
Director
Oct 27 '25
Sale
35.57
60,000
2,134,278
30,000
Lian Brian
President & CEO
Oct 28 '25
Sale
35.01
38,989
1,364,923
2,419,109
ZANTE GREG
Chief Financial Officer
Oct 28 '25
Sale
35.00
6,185
216,481
173,592
$38.39
price down icon 1.08%
$95.41
price down icon 0.72%
$31.31
price down icon 3.07%
$94.81
price down icon 1.24%
biotechnology ONC
$319.06
price down icon 0.55%
$197.01
price up icon 0.91%
Kapitalisierung:     |  Volumen (24h):